Patrick G. Lepore - Nov 30, 2021 Form 4 Insider Report for VYNE Therapeutics Inc. (VYNE)

Role: Director
Signature: /s/ Mutya Harsch, attorney-in-fact for Patrick LePore
Stock symbol: VYNE
Transactions as of: Nov 30, 2021
Transactions value $: $12,699
Form type: 4
Date filed: 12/2/2021, 04:08 PM
Previous filing: Nov 30, 2021
Next filing: Feb 10, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VYNE	Common Stock	Purchase	$12.7K	+12.5K	+25%	$1.02	62.5K	Nov 30, 2021	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares were purchased pursuant to a 10b5-1 plan entered into by the reporting person on April 21, 2021.
F2	The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.98 to $1.03, inclusive. The reporting person undertakes to provide to VYNE Therapeutics Inc., any security holder of VYNE Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Content

Shares were purchased pursuant to a 10b5-1 plan entered into by the reporting person on April 21, 2021.

The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.98 to $1.03, inclusive. The reporting person undertakes to provide to VYNE Therapeutics Inc., any security holder of VYNE Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.